TISSUE-TYPE plasminogen activator (t-PA) is a naturally occurring serum protein with high affinity for fibrin. It activates plasminogen and induces fibrinolysis physiologically or pharmacologically. Since the Km (Michaelis constant) of t-PA for free plasminogen is so much greater (65 gM) than the Km for plasminogen bound to fibrin (0.14 ,M), essentially no conversion of plasminogen to plasmin occurs in the circulation
TISSUE-TYPE plasminogen activator (t-PA) is a naturally occurring serum protein with high affinity for fibrin. It Widespread clinical application of t-PA requires production methods capable of large yields of biologically active material. To this end, human tissue-type plasminogen activator has been produced in large quantities with the use of recombinant DNA technology (rt-PA). 7 We have recently pointed out that "clot selectivity"
of an activator of the fibrinolytic system with a finite although low affinity for circulating plasminogen is related to the time-activity curve of the concentration of activator in plasma associated with any given dosage regimen. Blood samples were obtained before infusion of rt-PA; at the end of the initial infusion to provide an estimate of peak levels; 5, 10, and 15 min after the infusion had been completed (for determination of the half-lives of immunoassayable rt-PA and functional activity); and 30 min and 3 hr after completion of the infusion. In some patients samples were drawn 20, 30, 40, 50, and 60 min after initiation of infusion for determination of the time of occurrence of a plateau of blood level. Samples were assayed for immunoassayable t-PA, comprising endogenous t-PA and exogenous rt-PA, t-PA functional activity, a2-antiplasmin, plasminogen, fibrinogen, fibrinogen degradation products, prothrombin time, activated partial thromboplastin time, and protamine-corrected thrombin time as follows.
Collection of samples. Venous blood was acquired with a two-syringe technique to avoid contamination of samples with products within the dead space of the indwelling venous catheters used. Samples were placed immediately on ice in Vacutainer tubes containing citrate. Aliquots for determination of fibrinogen were placed in tubes of the same type supplemented with aprotinin (200 kallikrein inhibitor units [KIU]/ml blood) to inhibit fibrinogenolysis in vitro. Plasma was separated by centrifugation at 40 C and frozen at -700 C before assay.
In preliminary experiments blood samples supplemented with 42 nM rt-PA (approximating peak plasma concentrations in treated patients) with or without aprotinin were placed on ice for 0, 30, 60, 120, or 180 min before centrifugation and before freezing at -700 C. Plasma was thawed immediately before assay for t-PA antigen, t-PA functional (fibrinolytic) activity, plasminogen, and fibrinogen. Results of duplicate assays in each case showed that t-PA antigen levels did not decline throughout the 180 min interval of initial storage at 00 to 40 C, and in fact remained within 99% of initial values. t-PA functional activity did not decline detectably and fibrinogen content did not decrease by more than 10%. However, plasminogen decreased by 50% at the end of 1 hr and by 80% at the end of the 3 hr storage interval. The observed decreases in fibrinogen and plasminogen in samples stored for 3 hr at 00 to 40 C were reduced by 50% when samples were centrifuged at zero time and separated plasma was stored at 00 to 40 C for up to 3 hr before freezing at -700 C. No decreases were seen when samples were supplemented with only 0.7 nM t-PA. ATotal dose was calculated for each patient on the basis of body weight. The value shown for total dose is for an average 80 kg patient. As indicated in the text, the dosages used changed throughout the study in part because of its dose-finding nature and in part because of our interest in evaluating a range of blood levels.
These results indicated that assays of plasminogen in samples from patients treated with rt PA should be performed on plasma separated promptly from red cells and frozen quickly if spurious results reflecting activation of plasminogen in vitro are to be avoided. Accordingly, the procedures used in this study included prompt centrifugation and fast freezing of all samples.
Immunoassayable t-PA. A two-site immunoradiometric ass ay (IRMA) developed by Rijken et al. 10 was used to assay t-PA antigen as decribed previously.' Thawed, citrated plasma samples were diluted serially in buffer. Duplicate determinations were performed at each dilution. The purified human melanoma t-PA used to generate the standard curve and rabbit anti-t-PA were kindly provided by Dr. D. Collen.
t-PA functional activity. Functional fibrinolytic activity was measured on fibrin plates exposed to euglobulin fractions from patient samples as previously described.' Euglobulin fractions were prepared by dilution of citrated plasma ( 1:20) with distilled water, adjustment of pH to 5.6 with acetic acid, and centrifugat ion. Precipitates were resuspended in a volume equal to the original volume of citrated plasma with buffer containing 0.4% bovine serum albumin. Serial dilutions were spotted in duplicate on fibrin plates prepared conventionally with fibrinogen obtained from Kabi Diagnostica. After plates had been incubat ed at 37°C for 16 hr, zones of lysis were quantified by compari- 
Results
Clinical observations. Twelve patients were studied: seven men and five women 38 to 69 years of age (mean 56 yr). Six had complete occlusion of the right coronary artery (RCA), five had complete occlusion of the left anterior descending coronary artery (LAD), and one had a complete occlusion of the circumflex coronary artery. None manifested systemic bleeding or bleeding from arteriotomy sites in association with infusion of rt-PA (i.e., within 12 hr of infusion). Coronary thrombolysis was induced with rt-PA in 10 of the 12 patients (83%) (four of four given rt-PA by the 112 intracoronary route and six of eight given the agent intravenously) by an average of 7 hr after the onset of symptoms (range -4 hr 20 min to 10 hr 30 min) and was documented angiographically (figure 1). In nine patients, the onset of lysis was demonstrated within 15 to 30 min after the onset of the infusion of rt-PA, and lysis was complete within 45 min. In the tenth patient lysis was evident within 90 min after the onset of infusion. FIGURE 1. Serial angiograms of the right coronary artery (right anterior oblique projection) from a representative patient given intravenous rt-PA. Initially, the vessel is totally obstructed proximally (A). Fortyfive minutes after the onset of infusion of rt-PA patency is restored but a residual high-grade stenosis is evident (arrow in B), which persisted unchanged for 2 weeks. At :ed by rt-PA in two patients. levels were generally proportional to dose (figure 2 all patients with heparin at the time of cardiac catheterization. However, protamine-corrected thrombin time averaged 15.7 sec 90 min after the onset of infusion of rt-PA and 15. 1 sec 3 hr after the completion of infusion (normal range <18.5 sec). Furthermore, fibrinogen degradation product titers determined 15 to 30 min after infusion of rt-PA averaged 1:16 (range 1:1 to 1:64). Thus, infusion of rt-PA did not impair the integrity of the coagulation system as assessed in vitro.
Discussion
With the use of computer simulations we have previously estimated the ranges of blood levels of t-PA likely to be effective yet safe.8 However, several factors may give rise to considerable variability in the response of the fibrinolytic system to markedly elevated blood levels of t-PA, including differences in pretreatment levels of a2-antiplasmin and other inhibitors of plasmin, prevailing levels of inhibitors of t-PA, and concomitant activation of plasminogen in vivo through alternative pathways such as the factor XlIa-dependent pathway among others. Thus, although reasonable hypothetical limits for the upper bound of blood levels of t-PA likely to be desirable have been identified, direct measurements of changes in blood levels of t-PA and of the response of the fibrinolytic system to infusion of rt-PA were believed to be needed.
The results obtained in this study have several potentially practical implications. They indicate that pharmacologic blood levels of rt-PA within selected ranges can be achieved and sustained in a dose-dependent fashion in patients treated for coronary thrombolysis with parenteral infusions of the agent. The relatively short half-life demonstrable for t-PA antigen is paralleled by the half-life of functional activity. Taken together, the disappearance curves of immunoassayable and functional t-PA activity suggest that administration of rt-PA does not give rise to immunoreactive denatured products on the one hand or to functionally active but immunounreactive fragments on the other. The short half-life of rt-PA and the lack of elaboration of functionally active fragments during the course of infusions of rt-PA probably contributed to the absence of prolonged adverse effects on the hemostatic system, in contrast to the case after infusion of conventional activators of the fibrinolytic system such as streptokinase." 17 Overall, in the group of patients given rt-PA, depletion of circulating fibrinogen was modest, depletion of circulating plasminogen was incomplete, and prolongation of the prothrombin time and/or protamine-corrected thrombin time was clinically insignificant.
However, as anticipated from consideration of the kinetics of the multiple reactions involved in fibrinolysis and conditions affecting their rates and interactions,8 conversion of circulating plasminogen to plasmin can be induced by high doses of rt-PA. Thus, it is not surprising that some consumption of a2-antiplasmin and some depletion of circulating plasminogen occurred.
This study evaluated a relatively small number of patients exposed to a limited range of doses of rt-PA. Effects of even higher blood levels of t-PA activity or more prolonged elevations cannot be extrapolated a priori from the data available. Since t-PA is cleared by the liver, 18 blood levels in patients with marked impairment of liver function can be anticipated to differ from those in patients without such impairment.
Because of the higher affinity of t-PA for plasminogen bound to fibrin compared with its affinity for free, circulating plasminogen, infusion of rt-PA offers promise for coronary thrombolysis without concomitant induction of a systemic bleeding diathesis. The short half-life of rt-PA delineated in this study should facilitate prompt achievement of a desired steady-state plasma level with a given dose regimen. In addition, it should provide protection by facilitating a prompt decrease of t-PA activity to normal in blood relatively soon after cessation of an infusion of rt-PA. Such reductions are likely to be advantageous in patients who may require emergency surgery or other invasive procedures soon after treatment with rt-PA.
